| Document |
Document Title |
|
WO/2024/077531A1 |
The present invention relates to gene segregation and plant improvement, and in particular, to an anti-spotted wilt gene RTSW from tobacco and a use thereof. Provided are a nucleic acid molecule for conferring or enhancing the resistance...
|
|
WO/2024/052734A3 |
The application provides circular DNA vectors comprising promoters, scaffold matrix attachment region (S/MAR) sequences, and transgenes derived from proteins expressed in respiratory epithelium and which lack drug resistance genes. The a...
|
|
WO/2024/080451A1 |
The present invention relates to a method for preparing a high purity DNA fragment mixture using isopropanol and magnesium chloride, wherein impurities such as moisture, blood, and fat are effectively removed and the purity of the DNA fr...
|
|
WO/2024/081167A1 |
The present disclosure provides novel and efficient methods and lentiviral vectors for manufacturing a population of immune cells engineered to express a Chimeric Antigen Receptor (CAR), an engineered T cell receptor (TCR), and/or a nucl...
|
|
WO/2024/079221A1 |
An isolated protein comprising (i) a first protein moiety selected from the group of proteins comprising an amino acid sequence having at least 70% identity to residues 113-231 of 5 Bri2 from human (SEQ ID NO: 2); and proteins comprising...
|
|
WO/2024/081746A2 |
The present invention relates to nucleic acid expression cassettes that are engineered to enhance gene expression. Vectors and methods employing the expression cassettes containing novel chimeric regulatory elements are provided. The inv...
|
|
WO/2024/078485A1 |
The present invention belongs to the technical field of tumor immunotherapy, and specifically relates to a signal receptor used for targeting a tumor microenvironment and a cell for targeted treatment of tumors. The signal receptor compr...
|
|
WO/2024/080509A1 |
The present invention relates to an IGF-1 receptor-binding aptamer and a use thereof. The aptamer according to the present invention can function as a biased agonist selectively inducing only the metabolic function of the IGF-1 receptor ...
|
|
WO/2024/079662A1 |
Provided herein are improved expression constructs for the expression of UPF1 and vectors comprising such constructs. Also provided are methods of treating neurogenerative diseases, including, but not limited to, amyotrophic lateral scle...
|
|
WO/2024/081604A1 |
The present relates to polynucleotide constructs encoding an ApoE3 related protein optionally containing one or more intron. Potential uses of the different constructs include gene therapy targeting one or more disease or disorder, for e...
|
|
WO/2024/078614A1 |
Provided are an amino lipid compound for preparing a lipid nanoparticle for delivering an active ingredient and a preparation method therefor, a lipid nanoparticle and a pharmaceutical composition containing the amino lipid compound, and...
|
|
WO/2024/078643A1 |
Provided in the present invention are a genetically modified mouse cell, a mouse having a humanized immune system containing said mouse cell, and a construction method for the humanized mouse. The method comprises: inactivating a GFI1 ge...
|
|
WO/2024/081511A2 |
Disclosed herein are compositions and methods for one step CMC production of RNA therapeutic complexes (nanostructures) that contain nucleoside analogues. In some embodiments, the nucleoside analogues are incorporated into RNA oligonucle...
|
|
WO/2023/244992A3 |
Compositions and methods are provided for genome modification of a target sequence in the genome of a cell, using novel engineered Cas polypeptides. The engineered Cas polypeptides and related methods, systems and compositions disclosed ...
|
|
WO/2024/078038A1 |
Provided in the present invention are a wheat leaf rust resistance protein, and an encoding gene and the use thereof The wheat leaf rust resistant protein comprises any one of the following (a)-(c): (a) a protein, which consists of the a...
|
|
WO/2024/050376A3 |
Described herein is a novel enzymatic pathway and acid tolerant Schizosaccharomyces pombe strain exhibiting the same, for producing 3-hydroxypropionic acid by fermentation wherein the S. pombe strain includes nucleotide sequences that en...
|
|
WO/2024/080867A1 |
This invention relates to a method of measuring gene promotor activity and a training data set consisting of promoter activity measurements for each of a plurality of DNA fragments. The invention also relates to a computer-implemented me...
|
|
WO/2024/077478A1 |
The present invention relates to a method for preparing extracellular vesicles having reduced non-specific binding/endocytosis. By means of performing knocking out and deglycosylating operations on extracellular vesicle-related adhesion ...
|
|
WO/2024/081884A1 |
The present disclosure provides methods and compositions for the treatment of glycogen storage diseases (e.g., GSD IX). In some aspects, the present disclosure provides splice-switching oligonucleotides that correct splicing defects and ...
|
|
WO/2024/081847A1 |
An apparatus is described for concentrating biomolecules in solution, such as oligonucleotide-containing solutions, via tangential flow filtration (TFF), where the apparatus can concentrate the oligonucleotides to a concentration > 100 m...
|
|
WO/2024/081163A1 |
Provided herein are methods of treating leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation (LBSL) in a subject in need thereof, the method comprising: administering a therapeutic agent to the subject, wh...
|
|
WO/2024/015853A3 |
Disclosed herein are fusion proteins comprising the CR3 domain of the low density lipoprotein (LDLR) and a polypeptide with phase behavior. Also provided herein are polypeptides with phase behavior. Additionally provided herein are metho...
|
|
WO/2024/079655A1 |
The present disclosure provides methods for producing and purifying recombinant adeno associated virus (AAV) vectors, including separating of full capsids from empty capsids, using anion exchange chromatography in weak partitioning mode....
|
|
WO/2024/079460A1 |
The present invention relates to novel polypeptide ligands of CXCR1 and/or CXCR2 which are derived from GCP2. The invention also concerns polynucleotides encoding the polypeptide ligands, uses of the polypeptide ligands and compositions ...
|
|
WO/2024/079109A1 |
The invention relates to a genetically modified natural killer (NK) cell, comprising a nucleic acid sequence encoding a chimeric antigen receptor (CAR), wherein said CAR comprises an extracellular antigen-binding domain that specifically...
|
|
WO/2024/080311A1 |
[Problem] The present invention addresses the following to-be-solved problems: there are no gene introduction methods that have a high gene introduction efficiency and high specificity for skin, subcutaneous tissues, skin ulcer surfaces,...
|
|
WO/2024/081411A1 |
Described herein are recombinant polynucleotides encoding small RNA payloads, such as engineered guide RNAs. The small RNA payloads may include stability elements to increase stability of the small RNA payload encoded by the recombinant ...
|
|
WO/2024/079110A1 |
The invention relates to a nucleic acid construct for targeting and integrating a binding domain in- frame into an endogenous CD3 epsilon gene of a human cell. The invention further relates to a genetically modified human T cell comprisi...
|
|
WO/2024/081596A1 |
Provided herein is a method that involves lysing cells that have a fusion between a first gene and a second gene at an end of an electrophoresis gel, applying a voltage potential to the gel to intact genomic DNA at one end of the gel, di...
|
|
WO/2024/079137A1 |
There is disclosed a mutant, non-naturally occurring or transgenic plant or part of the plant having reduced or inhibited expression or activity of NtNTP2-T or reduced or inhibited expression or activity of NtNTP2-T and NtNTP2-S, said Nt...
|
|
WO/2024/044736A3 |
Described herein is a CRISPR guide and retron donor expressed separately to mediate genome editing by homology-directed repair. The split system works more efficiently than previous approaches employing retron-gRNA fusions, demonstrating...
|
|
WO/2024/078558A1 |
An anti-CD100 antibody and a use thereof, a pharmaceutical composition or pharmaceutical combination comprising the antibody, and a use thereof. Further provided are a polynucleotide encoding the antibody, an expression vector, and a met...
|
|
WO/2024/026287A3 |
Described herein are systems and methods of synthesizing a chemically modified RNA polynucleotide having a defined and stoichiometric amount of a modified uridine nucleotide analog. In some embodiments, the systems and methods may compri...
|
|
WO/2024/077815A1 |
Provided are an adeno-associated virus capsid protein mutant having an unactivated T cell targeting property and the use thereof. The mutant comprises a sequence as shown in any one of SEQ ID Nos. 9-12. The recombinant adeno-associated v...
|
|
WO/2024/081820A1 |
Provided herein are targeted lipid particles, such as targeted lentiviral particles, having a targeting agent that binds to a target molecule selected from the group consisting of ASCT1, ASCT2, CD105, CD110, CD117, CD133, CD146, CD164, C...
|
|
WO/2024/080304A1 |
One embodiment of the present invention makes it possible to express, in the form of a fusion protein with a serum albumin (SA), a physiologically active protein that is expressed in a low amount and/or is less active when a host cell su...
|
|
WO/2024/079358A1 |
The present invention relates to a modified live attenuated Gram-negative bacteria, wherein said bacteria has been modified in such a way that RNA molecules can be safely and efficiently delivered to target eukaryotic cells. As such, the...
|
|
WO/2024/078570A1 |
It relates to immune cells (e.g., T cells such as CAR-T cells, NK cells such as CAR-NK cells) modified to have no or reduced expression and/or function of one or more target proteins selected from the group consisting of: Signal Peptide ...
|
|
WO/2024/077547A1 |
The present invention relates to a B7H3/PDL1 bispecific antibody, and a pharmaceutical composition comprising same and a use thereof. The bispecific antibody can bind to B7H3 and PDL1 in a targeted manner, and comprises: a monoclonal ant...
|
|
WO/2024/079132A1 |
The invention relates to an adeno-associated virus (AAV) capsid fusion protein comprising comprises an insert comprising a binding domain for a cell surface molecule, in particular, a variable immunoglobulin domain of a heavy chain antib...
|
|
WO/2023/205693A3 |
Provided herein are nucleic acid constructs that comprise an inducible promoter. Dual expression systems are provided comprising two nucleic acid constructs or a single nucleic acid construct with two inducible promoters. Also provided a...
|
|
WO/2024/081970A2 |
The present invention relates to a series of antisense oligonucleotides containing morpholine 3- thiophosphoramidate nucleotides or morpholine 3-thiophosphoramidate and DNA/RNA (modified) nucleotides having phosphorothioates (pS) linkers...
|
|
WO/2024/078626A1 |
Provided is a method for enhancing gene knock-in efficiency mediated by a CRISPR gene editing system in cells, comprising placing the cells in contact with a DNA-dependent protein kinase (DNA-PK) inhibitor and a cell division cyclin 7 (C...
|
|
WO/2024/079530A2 |
The application relates to nucleic acid regulatory elements that are able to enhance expression of genes constitutively in a variety of tissues, or in particular tissues including the muscle. The application further relates to methods em...
|
|
WO/2024/040006A3 |
An artificial intelligence-based method for diagnosing cancer or determining susceptibility to cancer includes a step of obtaining a biological sample from a target subject (e.g., a human). The degree of methylation in one or a plurality...
|
|
WO/2024/077702A1 |
An alkaline protease mutant having an improved enzyme activity obtained by means of iterative saturation mutagenesis using overlapping PCR technology, and a preparation therefor and the use thereof. The alkaline protease gene apr from Ba...
|
|
WO/2024/081915A1 |
The present disclosure provides capture proteins for detection of antibodies specific for Kawasaki disease, methods of using the antibodies, and kits comprising the same.
|
|
WO/2024/080275A1 |
The present invention addresses the problem of providing a method whereby environmental DNA or environmental RNA can be captured using a carrier having a high holding force, and the captured environmental DNA or environmental RNA can sub...
|
|
WO/2024/081156A1 |
The present disclosure relates to compositions of matter and assay methods used to detect one or more non-nucleic acid targets of interest in a sample. The compositions and methods provide signal boost upon detection of non-nucleic acid ...
|
|
WO/2024/080682A1 |
The present invention provides a light chain mutant of botulinum toxin obtained by substituting a specific lysine with arginine in the light chain of botulinum toxin. The light chain mutant of botulinum toxin according to the present inv...
|
